Researchers from the Radiopharmaceutical Sciences Group of C2TN coordinate a new exploratory project in partnership with researchers and clinicians from the MD Anderson Cancer Center in the USA, to evaluate the translational potential of the theranostic radiopharmaceutical 64CuCl2 in advanced cell models of cancer. This project was approved in the area of medical physics in the last call of the UTAustin Portugal program and the team from Portugal is led by Filipa Mendes, Principal Investigator at C2TN.
C2TN coordinates a new Research Project in Medical Physics with the MD Anderson Cancer Center, USA
